Codman Neuro*, part of DePuy Synthes Companies of Johnson & Johnson, announced the European launch of the REVIVE™ SE Thrombectomy Device, a next generation clot removal device offering enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke. (1)
The announcement was made at the 5th Congress of European Society of Minimally Invasive Neurological Therapy (ESMINT) in Nice, where Codman Neuro is showcasing its range of neurovascular solutions and sponsoring symposia on the interventional treatment of acute stroke and the clinical experience with the enhanced REVIVE SE Thrombectomy Device.
The REVIVE SE device is a self-expanding basket made out of nitinol that features a closed-ended soft distal tip to capture clots and large fragments with minimal trauma. It is designed with narrower and taller struts than similar devices on the market to better penetrate and engage more clot (2) and lower the force required to pass the device through a 0.021 micro-catheter. (3) The REVIVE SE device may also be used for the non surgical removal of thrombi and emboli with aspiration and injected contrast agents.
"Our experience with the device has been excellent," said Professor Stefan Rohde, MD,** Head of the Department of Radiology and Neuroradiology at Klinikum Dortmund in Germany. "We are achieving consistently good recanalization rates and the enhanced navigation eases passage through the cerebral vasculature to the thrombus, which is very important in a time-sensitive operation of this kind."
CE marking for the latest REVIVE SE device was obtained by Codman Neuro in June 2013. Several institutions in Germany, France, Italy, United Kingdom, Portugal, Spain, Belgium, the Netherlands, Israel, Denmark, Slovakia and Turkey have already begun using the device. The REVIVE SE device is not currently approved for distribution in the United States.
“Feedback throughout Europe has been very positive and we are seeing great interest in the REVIVE SE device at ESMINT," said P. Laxmin Laxminarain, Worldwide President of Codman Neuro. "We believe the device will become an increasingly important treatment option for ischemic stroke patients at institutions throughout Europe."
According to the European Society of Cardiology, stroke is the second most common cause of death in Europe resulting in almost 1.1 million deaths each year. About 15 percent of women and about 10 percent of men die from the disease. (4) According to the World Health Organization (WHO), 15 million people worldwide have a stroke each year. About one-third of stroke victims die and another third are left permanently disabled. (5)
About Codman Neuro
Codman Neuro is a global neurosurgery, neurovascular and neuromodulation company that offers a broad portfolio of devices for hydrocephalus management, neuro intensive care and cranial surgery as well as aneurysm coils, vascular reconstruction devices and other technologies used in the endovascular treatment of cerebral aneurysms and stroke. Codman Neuro is part of DePuy Synthes Companies of Johnson & Johnson. Visit www.codman.com and www.depuysynthes.com for more information.
(1) Data on file at Codman Neuro
(2) Data on file at Codman Neuro
(3) Test reports on file at Codman Neuro
(4) http://www.escardio.org/about/press/press-releases/pr-12/Pages/world-heart-day-new-european-statistics-heart-disease-stroke.aspx: accessed Aug. 2013
(5) http://www.emro.who.int/health-topics/stroke-cerebrovascular-accident/: accessed Aug. 2013
* Codman Neuro is a division of DePuy Orthopaedics, Inc.
** Consultant to Codman Neuro